Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Cited In for PubMed (Select 15307000)

1.

The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany.

Weinke T, Glogger A, Bertrand I, Lukas K.

ScientificWorldJournal. 2014;2014:749698. doi: 10.1155/2014/749698. Epub 2014 Dec 8.

2.

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ.

Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670.

PMID:
25424815
3.

Acupuncture for postherpetic neuralgia: a systematic review protocol.

Li W, Peng W, Zhou J, Liu Z.

BMJ Open. 2014 Nov 12;4(11):e005725. doi: 10.1136/bmjopen-2014-005725.

4.

ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?

Duracinsky M, Paccalin M, Gavazzi G, El Kebir S, Gaillat J, Strady C, Bouhassira D, Chassany O.

BMC Infect Dis. 2014 Oct 1;14:529. doi: 10.1186/1471-2334-14-529.

5.

Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study.

Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R.

BMC Infect Dis. 2014 Jul 20;14:402. doi: 10.1186/1471-2334-14-402.

6.

Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study.

Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R.

Health Qual Life Outcomes. 2014 Jun 11;12:92. doi: 10.1186/1477-7525-12-92.

7.

Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.

Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS.

J Infect Dis. 2014 Nov 15;210(10):1573-81. doi: 10.1093/infdis/jiu279. Epub 2014 May 13.

PMID:
24823623
8.

Superficial cervical plexus block for management of herpes zoster neuralgia in the C3 dermatome: a case report.

Shin HY, Kim DS, Kim SS.

J Med Case Rep. 2014 Feb 19;8:59. doi: 10.1186/1752-1947-8-59.

9.

Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study.

Carroll S, Gater A, Abetz-Webb L, Smith F, Demuth D, Mannan A.

BMC Res Notes. 2013 Nov 25;6:486. doi: 10.1186/1756-0500-6-486.

10.

Incidence of herpes zoster in patients with altered immune function.

Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ.

Infection. 2014 Apr;42(2):325-34. doi: 10.1007/s15010-013-0550-8. Epub 2013 Nov 10.

11.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

12.

Silicone-acyclovir controlled release devices suppress primary herpes simplex virus-2 and varicella zoster virus infections in vitro.

Berkower CL, Johnson NM, Longdo SB, McGusty-Robinson SO, Semenkow SL, Margulies BJ.

Adv Pharmacol Sci. 2013;2013:915159. doi: 10.1155/2013/915159. Epub 2013 Aug 4.

13.

Herpes zoster vaccine in Korea.

Choi WS.

Clin Exp Vaccine Res. 2013 Jul;2(2):92-6. doi: 10.7774/cevr.2013.2.2.92. Epub 2013 Jul 3.

14.

Presentation and management of herpes zoster (shingles) in the geriatric population.

Cohen KR, Salbu RL, Frank J, Israel I.

P T. 2013 Apr;38(4):217-27. No abstract available.

15.

Assessment of vaccine candidates for persons aged 50 and older: a review.

Eilers R, Krabbe PF, van Essen TG, Suijkerbuijk A, van Lier A, de Melker HE.

BMC Geriatr. 2013 Apr 15;13:32. doi: 10.1186/1471-2318-13-32. Review.

16.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Review.

17.

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A.

Hum Vaccin Immunother. 2013 Apr;9(4):858-64. doi: 10.4161/hv.23412. Epub 2013 Jan 14.

18.
19.

Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece.

Lionis CD, Vardavas CI, Symvoulakis EK, Papadakaki MG, Anastasiou FS, Antonopoulou MD, Apostolakis CM, Dimitrakopoulos SA, Fountakis GI, Grammatikopoulos IA, Komninos JD, Kounalakis DK, Ladoukaki ES, Makri KV, Petraki CS, Ploumis NG, Prokopiadou DP, Stefanaki IN, Tsakountakis NA, Tsiligianni IG, Tzortzis EN, Vasilaki AA, Vasilopoulos TK, Vrentzos GE.

BMC Fam Pract. 2011 Dec 6;12:136. doi: 10.1186/1471-2296-12-136.

20.

Herpes zoster and postherpetic neuralgia surveillance using structured electronic data.

Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R.

Mayo Clin Proc. 2011 Dec;86(12):1146-53. doi: 10.4065/mcp.2011.0305. Epub 2011 Oct 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk